The College is pleased to have endorsed the British Society for Haematology report “The Haematology Workforce: A Comprehensive View.”
This report highlights the vital role of clinical pathology and laboratory services in the rapid diagnosis and management of haematological diseases.
The report reveals the growing pressure on haematology professionals, as the gap between workforce capacity and clinical demand continues to widen.
Supporting these findings, the College’s 2025 Workforce Census finds that 82% of haematologists believe current staffing levels are insufficient to ensure the long-term sustainability of services.
The College agrees that robust workforce planning is essential to align haematology services with local and regional needs – factoring in population growth, diagnostic demand, evolving working patterns, and succession planning.
Action and investment are urgently needed to future-proof the haematology workforce and ensure equitable access to high-quality care for all affected by blood diseases.
New CME Slideset: Frontline Management of Transplant-Ineligible Multiple Myeloma
For patients who have deferred or are ineligible for transplant, treatment decisions carry real weight. This slideset outlines how to integrate anti-CD38–based regimens and optimize supportive care to improve outcomes.
📥 Download now to bring evidence-based strategies into your next patient discussion: https://lnkd.in/eVKhipg5
Just published in Nature Reviews Disease Primers during #EHA2026. Chronic GvHD remains the leading cause of non-relapse mortality and one of the greatest unmet needs after allogeneic transplantation. This comprehensive review captures where we stand today, and where the field is heading tomorrow: from disease biology and biomarkers to novel therapies and personalized care. The mission is no longer just to help patients survive transplantation, but to help them live well after it. International Academy for Clinical Hematology (IACH) Nature European Hematology Association (EHA) EBMT Institut Universitaire de Cancérologie AP-HP Sorbonne Université FHU S2C-HOPE Sorbonne Université AP-HP, Assistance Publique - Hôpitaux de Paris Hopital Saint-Antoine Vanderbilt University Medical Center Inserm CRSA PARIS
The interim futility analysis for cema-cel, just gave the lymphoma field something to think about. A 41.6% absolute difference in MRD negativity at Day 45 versus observation, with clean tolerability, availability in community hospitals and most patients managed as outpatients. It is a meaningful signal that allogeneic CAR-T can work in first-line consolidation post R-CHOP.
What about the patients who relapse after cema-cel? Go back to CD19 with an autologous product: Yescarta, Breyanzi? They all target the same CD19 as cema-cel. Would a second CD19 CAR-T be reimbursed? If cema-cel moves towards commercialization in LBCL, patients who relapse will need a subsequent differentiated option. The commercial case for CD19-targeted autologous therapies in this setting will need rethinking.
This is where eti-cel becomes relevant. A highly differentiated product also developed at Cellectis, on the same backbone as cema-cel (originated from Cellectis platform), eti-cel targets both CD20×CD22 simultaneously. Data at the current dose show 88% ORR and 63% CR in heavily pretreated patients, a strong signal for a dual allogeneic approach.
Fifteen years ago, CAR-T emerged as a revolution. The real breakthrough, the bona fide pharmaceutical product, is allogeneic. Off-the-shelf, scalable, standardized. It will establish a new order in cell therapy. Autologous therapies are a process and will, in time, disappear.
On in vivo CAR-T: the science is early, the toxicity profile remains unfavorable today, and the regulatory path for a therapy where the vector is the product is, at best, unclear.
Cellectis Allogene Therapeutics Kite Pharma Bristol Myers Squibb Novartis Johnson & Johnson Gilead Sciences #dlcl #CART #celltherapy #allogeneic | 14 comments on LinkedIn
On behalf of the International Society for Laboratory Hematology (ISLH), we cordially invite you to attend the International Symposium on Technological Innovations in Laboratory Hematology.
The College is pleased to have endorsed the British Society for Haematology report “The Haematology Workforce: A Comprehensive View.”
This report highlights the vital role of clinical pathology and laboratory services in the rapid diagnosis and management of haematological diseases.
The report reveals the growing pressure on haematology professionals, as the gap between workforce capacity and clinical demand continues to widen.
Supporting these findings, the College’s 2025 Workforce Census finds that 82% of haematologists believe current staffing levels are insufficient to ensure the long-term sustainability of services.
The College agrees that robust workforce planning is essential to align haematology services with local and regional needs – factoring in population growth, diagnostic demand, evolving working patterns, and succession planning.
Action and investment are urgently needed to future-proof the haematology workforce and ensure equitable access to high-quality care for all affected by blood diseases.
Hemophagocytic lymphohistiocytosis (HLH) is a severe and life-threatening syndrome characterized by overwhelming inflammation that often leads to multiorgan…
Just published in HemaSphere Journal: EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation. https://lnkd.in/eSJ4k276
If you like to know more about these new guidelines, you can follow the session at #EHA2026 Thursday June 11, 13:15 in Hall A2-3 in Stockholm or online: https://lnkd.in/e-secB-n
Immune cells continually detect, engulf, and destroy invasive microbes and cancer cells.
This process, called phagocytosis, is carried out by macrophages that must distinguish between proengulfment signals and inhibitory (“don’t-eat-me”) warnings. Cluster of differentiation 47 (CD47), a cell-surface receptor, is the archetypal don’t-eat-me signal. Many cancers upregulate CD47 expression to escape phagocytosis, and CD47 blockade promotes phagocytosis of cancer cells in mice.
However, CD47 blockers have not shown clinical benefits in patients with acute myeloid leukemia (AML), an aggressive cancer of blood immune cells. This discrepancy has raised the possibility that the molecular programs that inhibit phagocytosis differ between mice and humans.
In a new Science study, researchers report that the mechanisms that control macrophage function in human and mouse cells are indeed different. They also identify cluster of differentiation 43 (CD43) as a potential target for human AML treatment.
𝗜𝗺𝗺𝘂𝗻𝗼𝘀𝗲𝗻𝗲𝘀𝗰𝗲𝗻𝗰𝗲 is a multimodal immune system remodeling process that includes inflammation, cellular senescence, T-cell fatigue, and thymic involution, all of which raise the risk of infection and disease as we age. Our review published in Current Opinion in Immunology https://lnkd.in/efRp3D4M highlights that centenarians often exhibit adaptive remodeling and maintained immune balance rather than a uniform decline. This includes retention of naïve T cells, expansion of cytotoxic T cell subsets, and regulated inflammatory signaling.
➡️ Immunosenescence should be viewed as a trajectory-dependent process in which balanced immune function determines resilience and healthy aging.
➡️ Progress in understanding immunosenescence is dependent on integrating longitudinal multi-omics data to generate biological-age biomarkers and inform immunometabolic or senotherapeutic techniques for extending healthspan. Thanks to coauthors Ivan David Lozada Martinez, MD, MSc Yeny Acosta Ampudia Gabriel Tobón
Every second, your body creates 2 million brand new red blood cells. Did you know they all die in exactly 120 days and your spleen processes 200 billion dead cells daily? Follow for more mind-blowing health facts! #health #bloodcells #humanbody #biology #shorts
Peter Voorhees, MD, emphasizes the importance of carefully determined early regimens for smoldering myeloma and involving patients in treatment decisions.
🧬🏁 CAR-T in Multiple Myeloma is no longer just a response-rate story — it’s a race to the “start line.” BCMA CAR-T has reset expectations in relapsed/refractory MM… and now the field is pushing earlier. But this review makes one point crystal clear: randomized medians don’t tell you who actually reaches infusion or who survives the logistics. s41409-025-02787-9 🔥 What the phase 3 data proved (earlier lines) 📌 KarMMa-3: ide-cel beat standard regimens with PFS 13.8 vs 4.4 months (HR 0.49), deeper responses, and higher MRD negativity. 📌 CARTITUDE-4: cilta-cel delivered even stronger separation: PFS not reached vs 11.8 months (HR 0.26), plus improved MRD and an OS advantage in later analysis (HR 0.55). s41409-025-02787-9 ⚠️ What trials don’t capture (and practice can’t ignore) ⏳ Attrition before infusion is real early deaths often occur in patients who never receive CAR-T while waiting through bridging + manufacturing windows. 🏭 Vein-to-vein (V2V) and “brain-to-vein” delays shape outcomes as much as biology. 🧪 Out-of-spec (OOS) products and manufacturing variability are not edge cases in the real world. s41409-025-02787-9 🧠 Product-specific reality: ide-cel vs cilta-cel ✅ The review highlights a consistent signal: cilta-cel tends to deliver deeper and more durable responses, but with more infections and distinct delayed neurotoxicity patterns that require long-horizon vigilance. s41409-025-02787-9 🛡️ The real battlefield: cytopenias + infections After the acute CRS/ICANS window, the dominant risks become: 🩸 prolonged cytopenias (ICAHT) + 🦠 infections, driving non-relapse mortality in routine care and strongly influenced by bridging intensity and baseline inflammatory/hematologic risk tools (e.g., CAR-HEMATOTOX; albumin+CRP). s41409-025-02787-9 🚀 What could move the start line forward 🎯 Beyond-BCMA targets (GPRC5D) 🧬 dual/multi-antigen CARs to curb escape (especially in EMD / post-BCMA) 🏭 next-day / point-of-care manufacturing 🧊 allogeneic off-the-shelf strategies 🧫 even in vivo CAR concepts designed to bypass apheresis and ex vivo manufacturing s41409-025-02787-9 💬 If CAR-T is moving earlier, the key question isn’t only “Can it beat SOC?” it’s “Can we deliver it fast, safely, and at scale?” #MultipleMyeloma #CarT #CiltaCel #IdeCel #CellTherapy #Immunotherapy #Hematology #Oncology #BCMA #GPRC5D
Over the past decades, the progressive identification of chromosomal abnormalities and gene mutations has transformed acute myeloid leukemia (AML) fro…
To get content containing either thought or leadership enter:
To get content containing both thought and leadership enter:
To get content containing the expression thought leadership enter:
You can enter several keywords and you can refine them whenever you want. Our suggestion engine uses more signals but entering a few keywords here will rapidly give you great content to curate.
Your new post is loading...
